IMPROVED IMMUNOGENICITY OF RECOMBINANT VACCINIA VIRUS-ANCHORED GP120 LACKING GP41

To produce a vaccine against human immunodeficiency virus-1 with impro ved immunogenicity, the transmembrane and cytoplasmic tail regions of human immunodeficiency virus-1 were replaced with those of the Vesicul ar Stomatitis Virus glycoprotein, and cloned into vaccinia virus. This recombinant vaccinia virus, vvE13, was compared to one expressing ful l length envelope gp160, vvE1. Env products of both were located on th e cell surface. Antibody response, lymphocyte proliferation and cytoto xicity were better with vvE13 than with vvE1 inoculated mice.